| 标题 |
Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow-up |
| 网址 | |
| DOI | |
| 其它 |
期刊:Journal of Clinical Oncology 作者:H. Yoon; K. Kato; Eric Raymond; R. Hubner; Yongqian Shu; et al 出版日期:2024-06-01 |
| 求助人 | |
| 下载 | 暂无链接,等待应助者上传 |
PDF的下载单位、IP信息已删除
(2025-6-4)